{"id":"W2916451481","doi":"10.1200/jco.18.01042","title":"First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre; Cegep de Saint Jerome","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; Eisai; Pfizer; Moderna; Incyte; Agios Pharmaceuticals; Syndax Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; University of Pennsylvania; Amgen; Jounce Therapeutics; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Cancer; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001312772,0.0004876697,0.000982292,0.0002642144,0.0001626232,0.0005348751,0.0004234082,0.0004509208,0.001063379],"category_scores_gemma":[0.0008221682,0.0002260217,0.0007508845,0.0001664874,0.0003252302,0.0003665038,0.0002144571,0.0008589322,0.0001570442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007022923,"about_ca_system_score_gemma":0.0004443364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004711337,"about_ca_topic_score_gemma":0.001413988,"domain_scores_codex":[0.9996231,0.0001851298,0.0000289844,0.00006305372,0.00005856283,0.00004125155],"domain_scores_gemma":[0.9992411,0.0001668197,0.0002871274,0.00004605799,0.00003812934,0.0002207897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.723124,0.01096647,0.1090335,0.000956081,0.001932783,0.0001221178,0.0001023562,0.003765265,0.04158352,0.000186727,0.001388622,0.1068385],"study_design_scores_gemma":[0.2571871,0.4117105,0.2963445,0.0001204645,0.002321776,0.000540118,0.00006317943,0.008847148,0.01903917,0.0002111205,0.00354423,0.00007066131],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997897,0.001302546,0.00009518229,0.00004322132,0.00001916508,0.0001448393,0.0001713473,0.00001334367,0.0003132686],"genre_scores_gemma":[0.9984525,0.0002804556,0.0002486356,0.0001084211,0.00003810398,0.0001055817,0.0003803046,0.00000213796,0.0003838443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001312772,"threshold_uncertainty_score":0.006942689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03760860318418664,"score_gpt":0.4112338146753233,"score_spread":0.3736252114911366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}